The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment

Growth Hormone and IGF Research

Volumn 25, Issue 4, 2015, Pages 174-181

  Espelund, Ulrick ^a,b   Grønbæk, Henning ^b   Villadsen, Gerda Elisabeth ^b   Simonsen, Kira ^b   Vestergaard, Poul Frølund ^b   Jørgensen, Jens Otto Lunde ^b   Flyvbjerg, Allan ^a,b   Vilstrup, Hendrik ^b   Frystyk, Jan ^a,b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biological assay; Hepatocellular carcinoma; Insulin like growth factor binding proteins; Insulin like growth factor I; Insulin like growth factor II; Kinase receptor activation assay; Liver cirrhosis

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; IGF1 PROTEIN, HUMAN; IGF2 PROTEIN, HUMAN; IGFBP-2 PROTEIN, HUMAN; IGFBP3 PROTEIN, HUMAN; PROINSULIN-LIKE GROWTH FACTOR II; PROTEIN PRECURSOR; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RADIOFREQUENCY ABLATION; TUMOR VOLUME; CASE CONTROL STUDY; LIVER TUMOR; METABOLISM; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; YOUNG ADULT;

EID: 84937520117     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2015.05.002     Document Type: Article

References (41)

1. EASL-EORTC guidelines EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012, 56:908-943.
2. Fabregat I., Roncero C., Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int. 2007, 27:155-162.
3. Martin J.L., Baxter R.C. Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3. Growth Factors 2011, 29:235-244.
4. Seccareccia E., Brodt P. The role of the insulin-like growth factor-I receptor in malignancy: an update. Growth Hormon. IGF Res. 2012, 22:193-199.
5. Livingstone C. IGF2 and cancer. Endocr. Relat. Cancer 2013, 20:R321-R339.
6. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 2000, 21:215-244.
7. Scharf J.G., Schmidt-Sandte W., Pahernik S.A., Ramadori G., Braulke T., Hartmann H. Characterization of the insulin-like growth factor axis in a human hepatoma cell line. Carcinogenesis 1998, 19:2121-2128.
8. Scharf J.G., Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm. Metab. Res. 2003, 35:685-693.
9. Breuhahn K., Schirmacher P. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J. Gastroenterol. 2008, 14:1690-1698.
10. Lin S.B., Hsieh S.H., Hsu H.L., Lai M.Y., Kan L.S., Au L.C. Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II. J. Biochem. 1997, 122:717-722.
11. Dong Z.Z., Yao D.F., Yao D.B., Wu X.H., Wu W., Qiu L.W., Jiang D.R., Zhu J.H., Meng X.Y. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J. Gastroenterol. 2005, 11:4655-4660.
12. El Tayebi H.M., Salah W., El Sayed I.H., Salam E.M., Zekri A.R., Zayed N., Salem E.S., Esmat G., Abdelaziz A.I. Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients. Biomarkers 2011, 16:346-354.
13. Qian J., Yao D., Dong Z., Wu W., Qiu L., Yao N., Li S., Bian Y., Wang Z., Shi G. Characteristics of hepatic IGF-II expression and monitored levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma. Am. J. Clin. Pathol. 2010, 134:799-806.
14. Rehem R.N., El-Shikh W.M. Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology 2011, 58:949-954.
15. Tsai J.F., Jeng J.E., Chuang L.Y., You H.L., Ho M.S., Lai C.S., Wang L.Y., Hsieh M.Y., Chen S.C., Chuang W.L., Lin Z.Y., Yu M.L., Dai C.Y. Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma. Tumour Biol. 2003, 24:291-298.
16. Morace C., Cucunato M., Bellerone R., De C.G., Crino S., Fortiguerra A., Spadaro F., Zirilli A., Alibrandi A., Consolo P., Luigiano C., Resta M.L., Ferrau O., Spadaro A. Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma?. Eur. J. Intern. Med. 2012, 23:e157-e161.
17. Chen J.W., Ledet T., Ørskov H., Jessen N., Lund S., Whittaker J., De Meyts P., Larsen M.B., Christiansen J.S., Frystyk J. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E1149-E1155.
18. Clemmons D.R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin. Chem. 2011, 57:555-559.
19. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
20. Llovet J.M., Fuster J., Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004, 10:S115-S120.
21. Simonsen K., Rode A., Nicoll A., Villadsen G., Espelund U., Lim L., Angus P., Arachchi N., Vilstrup H., Nexo E., Gronbaek H. Vitamin B12 and its binding proteins in hepatocellular carcinoma and chronic liver diseases. Scand. J. Gastroenterol. 2014, 49:1096-1102.
22. Vestergaard P.F., Hansen M., Frystyk J., Espelund U., Christiansen J.S., Jørgensen J.O., Fisker S. Serum levels of bioactive IGF1 and physiological markers of ageing in healthy adults. Eur. J. Endocrinol. 2014, 170:229-236.
23. Jeyaratnaganthan N., Grønbæk H., Holland-Fischer P., Espelund U., Chen J.W., Flyvbjerg A., Vilstrup H., Frystyk J. Ascites from patients with alcoholic liver cirrhosis contains higher IGF-I bioactivity than serum. Clin. Endocrinol. (Oxf.) 2009, 72:625-632.
24. Kamath P.S., Wiesner R.H., Malinchoc M., Kremers W., Therneau T.M., Kosberg C.L., D'Amico G., Dickson E.R., Kim W.R. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
25. Reinhard M., Frystyk J., Jespersen B., Bjerre M., Christiansen J.S., Flyvbjerg A., Ivarsen P. Effect of hyperinsulinemia during hemodialysis on the insulin-like growth factor system and inflammatory biomarkers: a randomized open-label crossover study. BMC Nephrol. 2013, 14:80.
26. Espelund U., Bruun J.M., Richelsen B., Flyvbjerg A., Frystyk J. Pro- and mature IGF-II during diet-induced weight loss in obese subjects. Eur. J. Endocrinol. 2005, 153:861-869.
27. Krassas G.E., Pontikides N., Kaltsas T., Dumas A., Frystyk J., Chen J.W., Flyvbjerg A. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J. Clin. Endocrinol. Metab. 2003, 88:132-135.
28. Friedrich N., Wolthers O.D., Arafat A.M., Emeny R.T., Spranger J., Roswall J., Kratzsch J., Grabe H.J., Hubener C., Pfeiffer A.F., Doring A., Bielohuby M., Dahlgren J., Frystyk J., Wallaschofski H., Bidlingmaier M. Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. J. Clin. Endocrinol. Metab. 2014, 99:1675-1686.
29. Wu Y.L., Ye J., Zhang S., Zhong J., Xi R.P. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J. Gastroenterol. 2004, 10:2740-2743.
30. Bonefeld K., Hobolth L., Juul A., Møller S. The insulin like growth factor system in cirrhosis. Relation to changes in body composition following adrenoreceptor blockade. Growth Hormon. IGF Res. 2012, 22:212-218.
31. Hoeflich A., Reisinger R., Lahm H., Kiess W., Blum W.F., Kolb H.J., Weber M.M., Wolf E. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?. Cancer Res. 2001, 61:8601-8610.
32. el Atiq F., Garrouste F., Remacle-Bonnet M., Sastre B., Pommier G. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int. J. Cancer 1994, 57:491-497.
33. Ho P.J., Baxter R.C. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin. Endocrinol. (Oxf.) 1997, 46:333-342.
34. Flyvbjerg A., Mogensen O., Mogensen B., Nielsen O.S. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J. Clin. Endocrinol. Metab. 1997, 82:2308-2313.
35. Lee D.Y., Kim S.J., Lee Y.C. Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J. Korean Med. Sci. 1999, 14:401-404.
36. Ranke M.B., Maier K.-P., Schweizer R., Stadler B., Schleicher S., Elmlinger M.W., Flehmig B. Pilot study of elevated levels of insulin-like growth factor-binding protein 2 as indicators of hepatocellular carcinoma. Horm. Res. 2003, 60:174-180.
37. Song B.C., Chung Y.H., Kim J.A., Lee H.C., Yoon H.K., Sung K.B., Yang S.H., Yoo K., Lee Y.S., Suh D.J. Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study. Cancer 2001, 91:2386-2393.
38. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273.
39. Scharf J.G., Unterman T.G., Kietzmann T. Oxygen-dependent modulation of insulin-like growth factor binding protein biosynthesis in primary cultures of rat hepatocytes. Endocrinology 2005, 146:5433-5443.
40. Frystyk J., Freda P., Clemmons D.R. The current status of IGF-I assays - a 2009 update. Growth Hormon. IGF Res. 2010, 20:8-18.
41. Wolthuis A. Impact of disease on interferences in blood bioanalysis. Bioanalysis 2011, 3:2223-2231.